off-label marketing

Pharmalot By Ed Silverman

FDA to hold two-day meeting on off-label drug marketing

Exclusive By David Armstrong

After patient death, N.J. attorney general seeks to suspend doctor who prescribed fentanyl

First Opinion By Juliet Preston

An alternative to the Hippocratic oath: ‘to not give up on patients’

Pharmalot By Ed Silverman

Two former device maker execs go on trial for unauthorized marketing

Pharmalot By Ed Silverman

Lawmakers accuse HHS of delaying FDA guidelines for off-label marketing

Pharmalot By Ed Silverman

Former Pfizer employee loses another bid to press illegal marketing lawsuit

Business By Associated Press

FDA settlement allows firm to promote ‘off-label’ use of fish-oil drug

Pharmalot By Ed Silverman

Pharma wants more freedom to pitch drugs. A separate review panel could be a problem